Randomized Phase II Trial of VK2809, an Investigational Thyroid Hormone Receptor Agonist, vs Placebo in NAFLD With Hyperlipidemia

April 10-14, 2019; Vienna, Austria
Patients treated with VK2809 for 12 weeks showed significantly reduced LDL-C and liver fat content vs those treated with placebo.
Format: Microsoft PowerPoint (.ppt)
File Size: 179 KB
Released: April 22, 2019


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Educational grant provided by:
Gilead Sciences

Related Content

Expert commentary on the evolving understanding of NAFLD and NASH pathobiology and promising progress toward effective treatment strategies

Manal F. Abdelmalek, MD, MPH Released: October 4, 2019

Expert overview of recommendations on screening, diagnosis, and treatment of nonalcoholic steatohepatitis (NASH).

Quentin M. Anstee, BSc, MB BS, PhD, MRCP(UK), FRCP
Program Director
Philip N. Newsome, PhD, FRCPE
Released: August 21, 2019

Audio from Clinical Care Options: Zobair Younossi, MD, discusses the clinical impact of the most important NAFLD/NASH data from EASL 2019 in Vienna.

Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Released: May 2, 2019

April 10-14, 2019; Vienna, Austria: Expert faculty members summarize key viral hepatitis studies from this important annual conference.

Nancy Reau, MD Zobair Younossi Headshot Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD Stefan Zeuzem, MD Released: April 30, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?